ERP29 (Endoplasmic Reticulum Protein 29, also known as ERP29) is a secretory pathway chaperone protein encoded by the ERP29 gene located on chromosome 12q13.13. This protein plays a critical role in endoplasmic reticulum (ER) function, protein folding, and quality control. ERP29 is increasingly recognized for its involvement in neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), where ER stress and protein misfolding are central pathogenic mechanisms.
The ERP29 gene spans approximately 8.5 kb and consists of 5 exons encoding a 246-amino-acid precursor protein[1]. The mature protein is secreted and contains a non-canonical KDEL-like retrieval sequence (QESPK) at its C-terminus, which distinguishes it from classical ER residents like GRP78/BiP[2]. ERP29 belongs to the ERp29 family of chaperones and possesses a characteristic thioredoxin-like domain structure[1:1].
ERP29 functions as a molecular chaperone that facilitates proper protein folding and assembly within the secretory pathway[1:2]. Unlike classical ER chaperones, ERP29 does not bind ATP but instead utilizes a substrate-binding mechanism to assist in the folding of secretory and membrane proteins[2:1]. It has been shown to be essential for the proper maturation of several proteins, including:
ERP29 contributes to ER quality control mechanisms by helping to retain improperly folded proteins within the ER lumen[3]. This function is critical for preventing the secretion of misfolded proteins that could disrupt cellular homeostasis.
In Alzheimer's disease, ERP29 has been implicated in the pathogenesis through several mechanisms[3:1][4]:
Amyloid precursor protein (APP) processing: ERP29 interacts with APP and influences its trafficking and proteolytic processing. Dysregulation of ERP29 may contribute to increased amyloid-beta (Aβ) production[3:2].
ER stress response: Accumulation of Aβ oligomers induces ER stress in neurons. ERP29 expression is upregulated as part of the unfolded protein response (UPR), but this adaptive response becomes maladaptive in chronic neurodegeneration[4:1].
Calcium homeostasis: ERP29 is involved in ER calcium store regulation. Disruption of calcium homeostasis is an early event in AD pathogenesis, and ERP29 dysfunction may exacerbate this impairment[3:3].
In Parkinson's disease, ERP29 involvement has been studied in the context of alpha-synuclein pathology[5]:
Alpha-synuclein aggregation: ER stress induced by alpha-synuclein accumulation upregulates ERP29 expression. However, chronic exposure to misfolded alpha-synuclein overwhelms protective ER responses[5:1].
Dopaminergic neuron vulnerability: The specialized ER architecture in dopaminergic neurons makes them particularly susceptible to ERP29 dysfunction[5:2].
Protein quality control failure: Impaired ERP29 function contributes to the failure of ER-associated degradation (ERAD), leading to accumulation of toxic protein aggregates[5:3].
ERP29 has been investigated in ALS research due to the central role of protein misfolding in this disease[6]:
TDP-43 pathology: ERP29 expression is altered in ALS motor neurons, potentially affecting TDP-43 trafficking and aggregation[6:1].
ER stress in motor neurons: Motor neurons exhibit heightened sensitivity to ER stress, and ERP29 dysfunction may contribute to their selective vulnerability[6:2].
ERP29 is widely expressed in human tissues, with high expression in:
In the brain, ERP29 is expressed in neurons and glia, with increased expression in reactive astrocytes surrounding neurodegenerative lesions[3:4][4:2].
Targeting ER stress pathways including ERP29 modulation represents a therapeutic strategy for neurodegenerative diseases[7]:
ER stress modulators: Small molecules that enhance ER chaperone function (e.g., ER stress inhibitors) are being investigated[7:1].
Gene therapy approaches: Viral vector-mediated delivery of ERP29 or related chaperones is under exploration[7:2].
Protein folding therapeutics: Pharmacological chaperones that assist ERP29 function are being developed[7:3].
ERP29 is an ER chaperone protein with important functions in protein folding, quality control, and cellular stress responses. Its dysregulation contributes to the pathogenesis of multiple neurodegenerative diseases through mechanisms involving ER stress, protein aggregation, and calcium homeostasis. Understanding ERP29 function and developing therapeutic modulators of this pathway represents an active area of neurodegeneration research.
Mkrtchian, S., et al. (1998). Cloning and sequence analysis of the human ERp29 gene encoding a secretory protein. Biochimica et Biophysica Acta. 1998. ↩︎ ↩︎ ↩︎
Barone, R., et al. (2014). ERp29 in protein secretion and disease. Journal of Cellular and Molecular Medicine. 2014. ↩︎ ↩︎
Hoozemans, J.J., et al. (2009). The unfolded protein response is activated in pretangle neurons in Alzheimer's disease brain. Brain Pathology. 2009. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Scheper, W., & Hoozemans, J.J. (2015). The unfolded protein response and proteostasis in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Credle, J.J., et al. (2015). Alpha-synuclein-mediated ER stress in Parkinson's disease. Molecular Neurobiology. 2015. ↩︎ ↩︎ ↩︎ ↩︎
Saxena, S., et al. (2009). ER stress and motor neuron vulnerability in ALS. Autophagy. 2009. ↩︎ ↩︎ ↩︎
Doyle, K.M., et al. (2011). Unfolded protein response pathways in neurodegenerative diseases. Journal of Alzheimer's Disease. 2011. ↩︎ ↩︎ ↩︎ ↩︎
Beyer, K., et al. (2006). Association of genetic variants in the ERp29 gene with Alzheimer's disease. Journal of Alzheimer's Disease. 2006. ↩︎